infliximab · Remicade

Monoclonal antibody

Also known as TA-650

Biosimilars tracked: infliximab-abda (Renflexis), infliximab-axxq (Avsola), infliximab-dyyb (Inflectra), infliximab-qbtx (Ixifi)

Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (4)
US
  • Ankylosing spondylitis and psoriatic arthritis
Product first approved 1998FDA label
CA
  • REMICADE® (infliximab) is indicated for: • use in combination with methotrexate for the reduction in signs and symptoms, inhibition of the progression of structural damage and improvement in physical function in adult patients with moderately to severely active rheumatoid arthritis. • the reduction of signs and symptoms and improvement in physical function in patients with active ankylosing spondylitis who have responded inadequately, or are intolerant to, conventional therapies. • reduction of signs and symptoms, induction and maintenance of clinical remission and mucosal healing and...
Product first approved 2001Health Canada
UK
  • Moderately to severely active Crohn's disease and ulcerative colitis in adults and paediatric patients
Product first approved 1999medicines.org.uk
EU
  • Rheumatoid arthritis Remicade, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate; adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs. In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated. Adult Crohn's disease...
Product first approved 1999EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (81)
Crohn's Disease
NCT06059989 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2021-11-25 – 2025-12 · Inflammatory Disease, Disease Crohn, Bowel Disease
What this study did
NCT02332356 · Tokyo Medical and Dental University
2014-09 – 2024-03 · Crohn Disease
What this study did
NCT01559142 · Children's Memorial Health Institute, Poland
2008-11 – 2012-12 · Crohn Disease
What this study did
NCT01661257 · Samsung Medical Center
2009-10 – 2011-06 · Crohn's Disease
What this study did
NCT00571337 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2005-12 – 2010-07 · Crohn Disease
What this study did
NCT00207675 · Centocor, Inc.
2003-02 – 2007-08 · Crohn Disease
What this study did
NCT00207766 · Centocor, Inc.
2000-06 – 2006-08 · Crohn Disease
What this study did
NCT00207662 · Centocor, Inc.
2000-07 – 2005-11 · Crohn Disease
What this study did
NCT00796250 · Merck Sharp & Dohme LLC
2003-11-01 – 2005-01-01 · Crohn's Disease
What this study did
Psoriasis
NCT00833053 · Merck Sharp & Dohme LLC
2009-10 – 2011-04 · Psoriasis
What this study did
NCT00527072 · Centocor Ortho Biotech Services, L.L.C.
2007-07 – 2009-10 · Psoriasis
What this study did
NCT00629772 · Innovaderm Research Inc.
2007-03 – 2009-07 · Palmoplantar Psoriasis
What this study did
NCT00687401 · Merck Sharp & Dohme LLC
2006-06 – 2009-05 · Psoriasis
What this study did
NCT00686686 · Merck Sharp & Dohme LLC
2007-12 – 2009-04 · Psoriasis
What this study did
NCT00358670 · Merck Sharp & Dohme LLC
2006-05 – 2009-01 · Psoriasis
What this study did
NCT00251641 · Merck Sharp & Dohme LLC
2005-09-01 – 2008-06-01 · Psoriasis
What this study did
NCT00254982 · Merck Sharp & Dohme LLC
2005-08 – 2006-09 · Psoriasis
What this study did
NCT00106834 · Centocor, Inc.
est. completion 2004-10 · Psoriasis
What this study did
Psoriatic Arthritis
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT01680159 · Tanabe Pharma Corporation
2012-07 – 2015-03 · Plaque Psoriasis, Psoriatic Arthritis, Pustular Psoriasis (Excluding a Localized), Psoriatic Erythroderma
What this study did
NCT00367237 · Merck Sharp & Dohme LLC
2006-05 – 2008-03 · Arthritis, Psoriatic
What this study did
Rheumatoid Arthritis
NCT03414502 · University of Nebraska
2007-12-10 – 2029-03 · Rheumatoid Arthritis
What this study did
NCT02990806 · Nichi-Iko Pharmaceutical Co., Ltd.
2017-01-19 – 2019-05-20 · Rheumatoid Arthritis
What this study did
NCT03147248 · Celltrion
2016-09-12 – 2019-04-15 · Rheumatoid Arthritis
What this study did
NCT01217086 · Celltrion
2010-10 – 2012-07 · Rheumatoid Arthritis
What this study did
NCT00394589 · Merck Sharp & Dohme LLC
2006-03 – 2008-10 · Rheumatoid Arthritis
What this study did
NCT00521924 · Merck Sharp & Dohme LLC
2007-06 – 2008-04 · Rheumatoid Arthritis
What this study did
NCT00691028 · Tanabe Pharma Corporation
2005-09 – 2007-05 · Rheumatoid Arthritis
What this study did
NCT00036374 · Centocor, Inc.
2001-10 – 2006-12 · Rheumatoid Arthritis, Juvenile
What this study did
NCT00202852 · Merck Sharp & Dohme LLC
2005-06-01 – 2006-03-01 · Arthritis, Rheumatoid
What this study did
NCT00317538 · Centocor Ortho Biotech Services, L.L.C.
2003-06 – 2004-11 · Rheumatoid Arthritis
What this study did
NCT00036387 · Centocor, Inc.
est. completion 2003-11 · Arthritis, Rheumatoid
What this study did
NCT00236028 · Centocor, Inc.
est. completion 2003-04 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT06614387 · JAROSLAW KIERKUS
2024-10-01 – 2028-11-30 · Ulcerative Colitis
What this study did
NCT03596645 · Janssen Research & Development, LLC
2018-10-29 – 2027-02-01 · Colitis, Ulcerative
What this study did
NCT02771457 · NYU Langone Health
2016-07 – 2019-07 · Inflammatory Bowel Disease
What this study did
NCT01551290 · Xian-Janssen Pharmaceutical Ltd.
2012-04 – 2014-10 · Ulcerative Colitis
What this study did
Phase 2/3 (7)
Crohn's Disease
NCT04974099 · Children's Hospital Medical Center, Cincinnati
2021-10-01 – 2024-08-01 · Crohn Disease
What this study did
NCT00269854 · Centocor, Inc.
1995-06 – 1996-10 · Crohn Disease
What this study did
Other / comorbidity
NCT04898231 · University of California, San Diego
2020-12-22 – 2024-04-25 · Multisystem Inflammatory Syndrome-Children
What this study did
NCT00521963 · HaEmek Medical Center, Israel
2010-03 – 2011-03 · Arthritis
What this study did
NCT00368264 · Medical University of Vienna
2006-09 – 2009-06 · Lupus Erythematosus, Systemic, Lupus Nephritis
What this study did
NCT00591201 · Hospital General de Mexico
2002-06 – 2007-09 · Spondylarthropathies
What this study did
NCT00443222 · Karolinska Institutet
— · Refractory Myositis
What this study did
Phase 2 (48)
Crohn's Disease
NCT01355614 · Novartis Pharmaceuticals
2011-06 – 2013-03 · Crohn's Disease
What this study did
Psoriasis
NCT00687362 · Merck Sharp & Dohme LLC
2006-05-30 – 2008-11-11 · Psoriasis
What this study did
NCT00230529 · Centocor, Inc.
est. completion 2003-01 · Psoriasis
What this study did
Rheumatoid Arthritis
NCT00207714 · Centocor, Inc.
2003-11 – 2006-02 · Rheumatoid Arthritis
What this study did
NCT00029042 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2002-01 – 2005-10 · Juvenile Rheumatoid Arthritis
What this study did
NCT00006292 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2000-09 – 2005-09 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT04305145 · Massachusetts General Hospital
2020-08-31 – 2030-06-30 · Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event
What this study did
NCT06136546 · Massachusetts General Hospital
2025-01-23 – 2029-01-31 · Depressive Disorder, Major, Inflammation
What this study did
NCT05034536 · Massachusetts General Hospital
2022-02-07 – 2028-12-31 · Metastatic Melanoma
What this study did
NCT07671222 · Instituto de Oftalmología Fundación Conde de Valenciana
2026-12 – 2028-03 · Sjogren Syndrome, Sjogren Syndrome With Keratoconjunctivitis, Dry Eye Disease (DED)
What this study did
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT07657312 · Naresh Bumma
2026-07-17 – 2027-12-31 · Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT06941376 · University of Pennsylvania
2025-11-11 – 2027-12 · Relapsing Polychondritis
What this study did
NCT03684278 · University of Liverpool
2019-05-01 – 2027-03-06 · Acute Pancreatitis
What this study did
NCT04438382 · ECOG-ACRIN Cancer Research Group
2021-01-07 – 2026-05-26 · Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis
What this study did
NCT05168475 · Cambridge University Hospitals NHS Foundation Trust
2021-07-14 – 2023-11-29 · Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome, Relapsing Polychondritis, Cryoglobulinemic Vasculitis, IgA Vasculitis, Polyarteritis Nodosa, Cutaneous Polyarteritis Nodosa, Primary Angiitis of Central Nervous System
What this study did
NCT04891991 · Cairo University
2021-11-26 – 2023-11-10 · Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy, Retinal Detachment
What this study did
NCT04564001 · Assistance Publique - Hôpitaux de Paris
2020-09 – 2023-09 · Takayasu Arteritis
What this study did
NCT04922827 · Jena University Hospital
2021-06-18 – 2023-07-01 · COVID-19
What this study did
NCT02495077 · National Institute of Allergy and Infectious Diseases (NIAID)
2015-11-02 – 2021-07-23 · Kidney Transplant
What this study did
NCT04425538 · Tufts Medical Center
2020-06-01 – 2021-01-22 · COVID-19
What this study did
NCT04114188 · Prof. Dr. Petra Reinke
2016-12-15 – 2020-12-31 · Renal Transplant Rejection
What this study did
NCT02251041 · Universitaire Ziekenhuizen KU Leuven
2014-09 – 2019-08 · Reperfusion Injury
What this study did
NCT02457585 · Seoul National University Hospital
2015-03 – 2018-04 · Takayasu's Arteritis
What this study did
NCT02363738 · University Health Network, Toronto
2015-09 – 2017-04 · Bipolar Depression
What this study did
NCT02763761 · Bristol-Myers Squibb
2016-08-16 – 2017-03-31 · Renal Cell Carcinoma, Melanoma, Lung Cancer
What this study did
NCT01485055 · Nationwide Children's Hospital
2011-12 – 2016-09-26 · Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease
What this study did
NCT00112749 · Jonsson Comprehensive Cancer Center
2005-02 – 2012-11 · Breast Cancer, Fatigue
What this study did
NCT00512278 · Nizar Zein
2007-07 – 2012-05 · Hepatitis C
What this study did
NCT01216631 · University of Leeds
2010-09 – 2011-08 · Spondylarthropathies
What this study did
NCT00372723 · Loyola University
2006-07 – 2011-06 · Toxic Epidermal Necrolysis
What this study did
NCT00514982 · National Institute of Allergy and Infectious Diseases (NIAID)
2007-08-07 – 2011-03-08 · Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
What this study did
NCT00823641 · Imperial College London
2008-10 – 2011-03 · HTLV-I-associated Myelopathy
What this study did
NCT00283712 · National Institute of Allergy and Infectious Diseases (NIAID)
2006-03 – 2011-03 · Pemphigus
What this study did
NCT00033891 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2002-04-10 – 2010-05-20 · Dermatomyositis, Polymyositis
What this study did
NCT00304954 · National Eye Institute (NEI)
2006-02 – 2010-01 · Age-Related Macular Degeneration, Choroidal Neovascularization
What this study did
NCT00175266 · University of Alberta
— · Type 1 Diabetes
What this study did
NCT00795574 · Florida Academic Dermatology Centers
2005-06 – 2008-08 · Hidradenitis Suppurativa
What this study did
NCT00201799 · Ohio State University Comprehensive Cancer Center
2004-02 – 2008-03 · Graft-Versus-Host Disease
What this study did
NCT00523354 · Swiss EE Study Group
2007-08 – 2007-10 · Esophagitis
What this study did
NCT00074074 · European Organisation for Research and Treatment of Cancer - EORTC
2003-10 – 2006-12 · Myelodysplastic Syndromes
What this study did
NCT00244179 · Charite University, Berlin, Germany
started 2003-01 · Reactive Arthritis
What this study did
NCT00753103 · University Hospital Birmingham NHS Foundation Trust
2003-01 – 2006-07 · Wegener's Granulomatosis, Renal Limited Vasculitis, Microscopic Polyangiitis
What this study did
NCT00060502 · Centocor, Inc.
2003-04 – 2006-02 · Cachexia, Pancreatic Neoplasms
What this study did
NCT00244192 · Center for Integrated Rehabilitation and Organ Failure Horn
2003-10 – 2005-12 · COPD, Cachexia
What this study did
NCT00604864 · KU Leuven
2004-02 – 2005-11 · Endometriosis
What this study did
NCT00076726 · Centocor, Inc.
2003-11 – 2005-07 · Giant Cell Arteritis
What this study did
Phase 1/2 (8)
Crohn's Disease
NCT00325078 · National Institute of Allergy and Infectious Diseases (NIAID)
2006-05 – 2012-06 · Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD)
What this study did
Other / comorbidity
NCT02638701 · University of California, San Francisco
2024-10-01 – 2028-12 · Aneurysm, Stroke, Vasculitis, Tumor Necrosis Factor-alpha
What this study did
NCT05180994 · Centre hospitalier de l'Université de Montréal (CHUM)
2022-05-01 – 2028-03-01 · Glaucoma Following Surgery
What this study did
NCT02126020 · James Chodosh, MD, MPH
2014-11 – 2017-04-03 · Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome, Mucous Membrane Pemphigoid
What this study did
NCT01256489 · Massachusetts Eye and Ear Infirmary
2010-12 – 2015-01 · Stevens-Johnson Syndrome, Corneal Blindness
What this study did
NCT00959725 · Icahn School of Medicine at Mount Sinai
2009-08 – 2011-08 · Diabetic Macular Edema
What this study did
NCT00958906 · Icahn School of Medicine at Mount Sinai
2009-08 – 2009-10 · Uveitic Macular Edema, Intraocular Inflammation
What this study did
NCT00111917 · Maier, Lisa, M.D.
2005-02 – 2009-01 · Berylliosis, Beryllium Disease
What this study did
Phase 1 (13)
Rheumatoid Arthritis
NCT04779892 · Taizhou Mabtech Pharmaceutical Co.,Ltd
2020-02-01 – 2020-06-15 · Rheumatoid Arthritis
What this study did
NCT01567358 · Nichi-Iko Pharmaceutical Co., Ltd.
2012-02 – 2013-04 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05912712 · Xijing Hospital of Digestive Diseases
2023-07-01 – 2025-12-31 · Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe, Rectal Ulcer
What this study did
NCT01971814 · University of California, San Francisco
2013-11 – 2015-01 · Ulcerative Colitis (UC), Inflammatory Bowel Disease
What this study did
Other / comorbidity
NCT03819296 · M.D. Anderson Cancer Center
2021-02-21 – 2026-10-31 · Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Pathologic Stage 0 Cutaneous Melanoma AJCC v8, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT02987686 · Centre hospitalier de l'Université de Montréal (CHUM)
2017-09-06 – 2025-11-15 · Sterile Corneal Melt
What this study did
NCT02359903 · Biocad
2015-02 – 2015-11 · Ankylosing Spondylitis
What this study did
NCT01220518 · Celltrion
2010-10 – 2012-06 · Ankylosing Spondylitis
What this study did
NCT00695682 · Retina Research Foundation
2008-06 – 2008-12 · Diabetic Retinopathy, Macular Degeneration
What this study did
NCT00075075 · National Eye Institute (NEI)
2003-12-23 – 2007-09-06 · Scleritis
What this study did
NCT00228839 · Emory University
est. completion 2006-10 · Graft vs Host Disease
What this study did
NCT00271570 · University of California, San Diego
2004-04 – 2006-10 · Kawasaki Disease
What this study did
Phase 4 (90)
Crohn's Disease
NCT07510191 · Sixth Affiliated Hospital, Sun Yat-sen University
2026-03-01 – 2029-12-31 · Crohn Disease (CD)
What this study did
NCT07415473 · Chinese Medical Association
2026-04-01 – 2029-03-31 · Crohn's Diseases
What this study did
NCT07417696 · Chinese Medical Association
2026-04-01 – 2029-03-31 · Crohn's Disease
What this study did
NCT05928039 · University of Calgary
2023-10-25 – 2028-12-31 · Crohn Disease
What this study did
NCT06051253 · Asan Medical Center
2023-11-01 – 2027-06-30 · Crohn Disease, Infliximab, Perianal Fistula Due to Crohn's Disease, Therapeutic Drug Monitoring, Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease Score
What this study did
NCT05906576 · Taizhou Mabtech Pharmaceutical Co.,Ltd
2023-09-21 – 2027-02 · Crohn Disease
What this study did
NCT05043870 · Children's Hospital of Fudan University
2022-10-10 – 2026-12-31 · Crohn Disease, Infliximab, Immunosuppression, Children, Only
What this study did
NCT05813860 · Sixth Affiliated Hospital, Sun Yat-sen University
2023-04-30 – 2026-10-31 · Crohn Disease, Infliximab
What this study did
NCT05072782 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2021-12-21 – 2026-10-15 · Crohn Disease
What this study did
NCT05552287 · Erasmus Medical Center
2023-08-02 – 2025-08 · Crohn Disease, Child, Only, Biologic; Inadequate
What this study did
NCT02517684 · Erasmus Medical Center
2015-04 – 2024-01 · Crohn's Disease
What this study did
NCT01817426 · Copenhagen University Hospital at Herlev
2013-01 – 2020-05 · Crohn Disease
What this study did
NCT01442025 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2012-06 – 2015-07 · Crohn's Disease
What this study did
NCT01880307 · Erasmus Medical Center
2013-01 – 2014-12 · Crohn's Disease
What this study did
NCT00851565 · Copenhagen University Hospital at Herlev
2009-06 – 2014-02 · Crohn's Disease
What this study did
NCT00752622 · Merck Sharp & Dohme LLC
2008-11 – 2010-06 · Crohn's Disease
What this study did
NCT00688636 · University of Pittsburgh
2005-01 – 2009-01 · Crohn's Disease
What this study did
NCT00554710 · Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
2001-05 – 2004-01 · Crohn's Disease
What this study did
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT06043752 · Ghurki Trust and Teaching Hospital
2022-03-10 – 2023-08-05 · Psoriasis
What this study did
NCT01237262 · University of Padova
2010-11 – 2010-11 · Moderate to Severe Psoriasis., Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.
What this study did
NCT00686595 · Merck Sharp & Dohme LLC
2007-10-01 – 2009-10-01 · Psoriasis
What this study did
Psoriatic Arthritis
NCT00432406 · Chinese University of Hong Kong
2006-05 – 2009-03 · Psoriatic Arthritis
What this study did
NCT00133315 · Hvidovre University Hospital
2004-09 – 2007-04 · Spondylarthropathies, Ankylosing Spondylitis, Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT01793519 · Georgetown University
2013-01 – 2024-08-30 · Rheumatoid Arthritis
What this study did
NCT01602302 · Medical University of Graz
2012-06 – 2020-11-19 · Rheumatoid Arthritis
What this study did
NCT02770794 · Chiba University
2016-04-01 – 2020-08-14 · Arthritis, Rheumatoid
What this study did
NCT02878161 · Fen Li
2016-01 – 2019-12 · Rheumatoid Arthritis
What this study did
NCT02353780 · Dr. Larry W. Moreland
2015-03 – 2018-11-30 · Rheumatoid Arthritis (RA)
What this study did
NCT01638715 · Medical University of Vienna
2012-05 – 2018-08-01 · Rheumatoid Arthritis
What this study did
NCT00908089 · University of Helsinki
2003-03 – 2015-12 · Rheumatoid Arthritis
What this study did
NCT01295151 · Julia Brown
2011-08 – 2015-11 · Rheumatoid Arthritis
What this study did
NCT02132234 · Jagiellonian University
2013-06 – 2014-07 · Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Hypertension
What this study did
NCT01000441 · University Hospital, Strasbourg, France
2009-12-23 – 2013-08-12 · Rheumatoid Arthritis
What this study did
NCT01072058 · University of Sao Paulo
2008-02 – 2011-02 · Arthritis, Rheumatoid, Spondylitis, Ankylosing
What this study did
NCT01308255 · University of Leeds
2006-09 – 2011-02 · Rheumatoid Arthritis
What this study did
NCT01282528 · Peking Union Medical College Hospital
started 2010-09 · Rheumatoid Arthritis, Ultrasonography, Infliximab
What this study did
NCT00462072 · University of Rochester
2007-03 – 2010-08 · Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease
What this study did
NCT00714493 · Centocor Ortho Biotech Services, L.L.C.
2008-07 – 2010-06 · Rheumatoid Arthritis
What this study did
NCT00216177 · Hvidovre University Hospital
2005-09 – 2009-06 · Rheumatoid Arthritis
What this study did
NCT00896168 · Xian-Janssen Pharmaceutical Ltd.
2007-06 – 2008-04 · Arthritis, Rheumatoid
What this study did
NCT00396747 · Université Catholique de Louvain
2003-06 – 2005-09 · Rheumatoid Arthritis
What this study did
NCT00794898 · Merck Sharp & Dohme LLC
2003-07-01 – 2004-04-01 · Arthritis, Rheumatoid
What this study did
NCT00246064 · Centocor Ortho Biotech Services, L.L.C.
2001-12 – 2003-11 · Arthritis, Rheumatoid
What this study did
Ulcerative Colitis
NCT07576452 · University Hospital, Clermont-Ferrand
2026-12-01 – 2030-12-01 · Ulcerative Colitis (UC)
What this study did
NCT04999228 · Children's Hospital of Fudan University
2021-11-01 – 2026-12-31 · Ulcerative Colitis, Infliximab, Children
What this study did
NCT06113913 · Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
2024-04-09 – 2026-11 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
What this study did
NCT04835506 · Beth Israel Deaconess Medical Center
2021-11-01 – 2026-09 · Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
What this study did
Early phase / not applicable (41)
Crohn's Disease
NCT05584228 · Nantes University Hospital
2026-10-01 – 2031-04-01 · Crohn Disease
What this study did
NCT07314606 · University of British Columbia
2026-04-22 – 2029-10-01 · Crohn Disease (CD), IBD (Inflammatory Bowel Disease), IBD - Inflammatory Bowel Disease
What this study did
NCT07424040 · The Children's Hospital of Zhejiang University School of Medicine
2026-03-01 – 2028-11-30 · Crohn's Diseases, Crohn's Disease in Pediatric Patient
What this study did
NCT07123207 · The Third Xiangya Hospital of Central South University
2025-08-04 – 2027-01-30 · Mild to Severe Crohns Disease
What this study did
NCT06064864 · Asan Medical Center
2023-10-09 – 2026-12-31 · Crohn's Disease
What this study did
NCT03393247 · Sixth Affiliated Hospital, Sun Yat-sen University
2017-06-01 – 2019-07-01 · Crohn Disease
What this study did
NCT02488005 · Icahn School of Medicine at Mount Sinai
2016-04 – 2017-08-17 · Crohn's Disease
What this study did
NCT01438151 · Shradha Agarwal
2011-12 – 2013-12 · Crohn's Disease
What this study did
NCT01266785 · Oregon Health and Science University
2010-12 – 2012-07 · Crohn's Disease
What this study did
NCT00252369 · Sheba Medical Center
— · Crohn's Disease
What this study did
Psoriasis
NCT01657513 · University Hospital, Gentofte, Copenhagen
2012-06 – 2013-07 · Psoriasis
What this study did
Rheumatoid Arthritis
NCT01915537 · Zhang, Xiao, M.D.
2013-08 – 2017-12 · Rheumatoid Arthritis(RA)
What this study did
NCT00901550 · Chinese University of Hong Kong
2008-11 – 2011-10 · Rheumatoid Arthritis
What this study did
NCT00948610 · University of California, Los Angeles
2008-11 – 2011-04 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT07149441 · Shanghai 10th People's Hospital
2025-08-01 – 2028-09-01 · Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis), Fecal Microbiota Transplantation
What this study did
NCT07470502 · Meyer Children's Hospital IRCCS
2025-02-13 – 2028-08-13 · IBD (Inflammatory Bowel Disease)
What this study did
NCT06758024 · Pontificia Universidad Catolica de Chile
2025-01-24 – 2028-01 · Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)
What this study did
NCT06839820 · University Hospital, Akershus
2025-02-01 – 2026-12 · Infliximab, Infusion, IBD (Inflammatory Bowel Disease), Patient Satisfaction
What this study did
NCT06381518 · Zuyderland Medisch Centrum
2024-03-12 – 2025-12-01 · IBD, Infliximab, Crohn Disease, Ulcerative Colitis
What this study did
NCT05722353 · Assistance Publique - Hôpitaux de Paris
2023-02-13 – 2025-11 · Inflammatory Bowel Diseases
What this study did
NCT05430412 · Adacyte Therapeutics SL
2022-01-11 – 2024-10 · Ulcerative Colitis
What this study did
NCT03841942 · University Hospital, Montpellier
2019-06-26 – 2023-10-31 · Inflammatory Bowel Diseases
What this study did
NCT04109300 · Western University, Canada
2020-09-01 – 2023-09-01 · Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
What this study did
NCT05291039 · Rehab Werida
2022-01-01 – 2023-04-01 · Inflammatory Bowel Diseases
What this study did
NCT03209232 · Schneider Children's Medical Center, Israel
2018-04-16 – 2021-09-01 · Ulcerative Colitis
What this study did
NCT02624037 · Icahn School of Medicine at Mount Sinai
2015-01 – 2020-10-21 · Inflammatory Bowel Disease
What this study did
NCT03370601 · University Hospital, Lille
2017-01-03 – 2019-01 · Inflammatory Bowel Diseases
What this study did
NCT01666535 · University of Calgary
2012-09 – 2013-08 · Inflammatory Bowel Disease
What this study did
NCT00791557 · University Hospitals Cleveland Medical Center
2008-10 – 2010-02 · Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
What this study did
NCT00586807 · Indiana University
2005-06 – 2008-09 · Ulcerative Colitis, Protein Metabolism, Energy Expenditure
What this study did
Other / comorbidity
NCT07257068 · M.D. Anderson Cancer Center
2026-12-31 – 2029-12-31 · Checkpoint Inhibitor, Pilot Study, Diabetes Melletus
What this study did
NCT07176754 · Peking University Third Hospital
2025-10-01 – 2028-10-31 · Cardiac Arrest (CA), Post Cardiac Arrest Syndrome
What this study did
NCT07491913 · Marmara University
2025-06-15 – 2027-12-15 · Takayasu Arteritis
What this study did
NCT02694588 · University Hospital Schleswig-Holstein
2014-06 – 2021-12 · IBD
What this study did
NCT01610947 · University Hospital, Montpellier
2012-05-14 – 2018-10-18 · Spondyloarthritis
What this study did
NCT01245361 · Patrick Durez
2007-11 – 2012-12 · Undifferentiated Arthritis
What this study did
NCT00237419 · Rheumazentrum Ruhrgebiet
2005-12 – 2011-04 · Ankylosing Spondylitis
What this study did
NCT02711202 · Institute for Clinical and Experimental Medicine
2007-01 – 2009-03 · Kidney Transplantation
What this study did
NCT00307593 · Assistance Publique - Hôpitaux de Paris
2004-05 – 2007-06 · Wegener's Granulomatosis, Churg-Strauss Syndrome, Microscopic Polyangiitis
What this study did
NCT00273390 · Oregon Health and Science University
2001-08 – 2006-12 · Uveitis
What this study did
Used as active comparator (32)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (15)
Crohn's Disease
NCT03221166 · IRCCS Burlo Garofolo
2018-02-27 – 2020-07-31 · Crohn Disease
What this study did
NCT02096861 · Celltrion
2014-09-19 – 2017-02-15 · Crohn's Disease
What this study did
Rheumatoid Arthritis
NCT04178850 · Genor Biopharma Co., Ltd.
2017-10-13 – 2021-04 · Rheumatoid Arthritis
What this study did
NCT03478111 · Shanghai Biomabs Pharmaceutical Co., Ltd.
2018-03-30 – 2019-08-27 · Rheumatoid Arthritis
What this study did
NCT02937701 · Amgen
2016-10-10 – 2018-08-13 · Arthritis, Rheumatoid
What this study did
NCT02683564 · Epirus Biopharmaceuticals (Switzerland) GmbH
2016-02 – 2017-07 · Rheumatoid Arthritis
What this study did
NCT01927263 · Nichi-Iko Pharmaceutical Co., Ltd.
2013-07 – 2016-03 · Rheumatoid Arthritis
What this study did
NCT01936181 · Samsung Bioepis Co., Ltd.
2013-08 – 2015-09 · Rheumatoid Arthritis
What this study did
NCT00095147 · Bristol-Myers Squibb
2005-02 – 2009-07 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
Other / comorbidity
NCT03112603 · Incyte Corporation
2017-06-29 – 2022-12-15 · Graft-versus-host Disease (GVHD)
What this study did
NCT02762812 · Biocad
2016-01 – 2017-07 · Ankylosing Spondylitis
What this study did
Phase 2 (5)
Rheumatoid Arthritis
Ulcerative Colitis
NCT06453317 · Medical University of Lodz
2025-02-17 – 2028-06-30 · Ulcerative Colitis, Inflammatory Bowel Diseases
What this study did
NCT07297069 · Asian Institute of Gastroenterology, India
2026-01-01 – 2027-12-31 · Acute Severe Ulcerative Colitis
What this study did
Other / comorbidity
NCT07619898 · Therakos LLC
2026-07 – 2029-12 · Colitis, Hepatitis, Melanoma (Skin Cancer)
What this study did
NCT06646016 · Therakos LLC
2025-12-15 – 2027-02-19 · Immune-related Colitis
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT04407247 · M.D. Anderson Cancer Center
2020-07-09 – 2027-12-31 · Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Melanoma
What this study did
Phase 1 (3)
Other / comorbidity
NCT01931189 · Nichi-Iko Pharmaceutical Co., Ltd.
2013-08 – 2014-01 · Healthy
What this study did
NCT01844804 · Pfizer
2013-05 – 2013-11 · Healthy
What this study did
NCT01922336 · Samsung Bioepis Co., Ltd.
2013-07 – 2013-10 · Healthy
What this study did
Phase 4 (6)
Crohn's Disease
NCT04530877 · Children's Hospital of Fudan University
2022-10-01 – 2024-09-30 · Crohn's Disease, Exclusive Enteral Nutrition, Infliximab, Mucosal Healing
What this study did
Rheumatoid Arthritis
NCT03100253 · Mario Negri Institute for Pharmacological Research
2018-03-01 – 2021-12-31 · Rheumatoid Arthritis
What this study did
NCT02148640 · Diakonhjemmet Hospital
2014-10 – 2017-01 · Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease, Psoriasis Chronic
What this study did
Ulcerative Colitis
NCT07550673 · Xijing Hospital of Digestive Diseases
2026-04-20 – 2028-11-01 · Acute Severe Ulcerative Colitis
What this study did
NCT05313620 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2022-04-01 – 2026-06-11 · Ulcerative Colitis, Thromboembolism
What this study did
NCT03151525 · Istituto Clinico Humanitas
2017-05-08 – 2020-04-03 · Colitis, Ulcerative
What this study did
Early phase / not applicable (2)
Crohn's Disease
NCT02998827 · Sixth Affiliated Hospital, Sun Yat-sen University
2016-11 – 2017-11 · Crohn Disease
What this study did
Ulcerative Colitis
NCT05931458 · Federico II University
2023-07-01 – 2028-07-01 · Ulcerative Colitis
What this study did
Appears in other studies (7)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2/3 (1)
Crohn's Disease
NCT05660746 · Children's Hospital Medical Center, Cincinnati
2023-07-01 – 2027-03-31 · Crohn Disease
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT04082910 · Chinese PLA General Hospital
2019-09-15 – 2023-12-30 · Solid Tumor, Hematological Malignancy
What this study did
NCT02620618 · Cairo University
2013-01 – 2014-12 · Behçet's Disease, Uveitis
What this study did
Phase 1 (1)
Other / comorbidity
NCT03293784 · Institut Claudius Regaud
2017-10-16 – 2023-08-10 · Melanoma
What this study did
Phase 4 (2)
Ulcerative Colitis
NCT05205603 · Sixth Affiliated Hospital, Sun Yat-sen University
2022-01-15 – 2025-01-15 · Ulcerative Colitis, Efficacy, Self, Biologics, Mesalazine
What this study did
NCT03885713 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2019-09-10 – 2024-12-31 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
What this study did
Early phase / not applicable (1)
Crohn's Disease
NCT04761952 · Sixth Affiliated Hospital, Sun Yat-sen University
2021-02-13 – 2023-12-31 · Inflammatory Bowel Diseases, Crohn Disease, Polyunsaturated Acid Lipidosis
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Ulcerative Colitis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Infliximab (Remicade): this drugApprovedMonoclonal antibodyTNF-alphaWeak signal
NCT01585155: Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%
NCT00336492: The Number of Participants With Clinical Response at Week 8 (Week 8): Infliximab 5 mg/kg 44/60 (73.3%)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00408629: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo)
NCT02065557: Induction (Week 8, ITT-E, Main Study): I-SD 43.3% vs external placebo 19.83% (p=0.382, NS); I-HD 59.6% vs external placebo (p<0.001); combined I-SD+I-HD 53.2% (p<0.001). Maintenance (Week 52, mITT-E): M-PL 33.3% (n=12, descriptive only); M-SD 29.0% vs external placebo 18.37% (p=0.382, NS); M-HD 45.2% (p<0.001); combined M-SD+M-HD 37.1% (p<0.001).
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Balsalazide Disodium (Colazal)
ApprovedUS marketing discontinued
Small moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Uceris Rectal Foam)ApprovedSmall moleculeGlucocorticoid receptorReliable signalNo reviewed efficacy summary in this indication
Budesonide MMX (Uceris)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT01532648: Registered primary, clinical remission at day 56 (UCDAI rectal bleeding and stool frequency subscores of 0), budesonide MMX 9 mg vs placebo added to oral mesalamine: 56/230 vs 52/228 (CT.gov); similar in both groups, p=0.70 (Rubin 2017). Combined clinical and endoscopic remission at week 8: 13.0% vs 7.5%, p=0.049. missed
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Etrasimod (Velsipity)ApprovedSmall moleculeS1P receptorReliable signal
NCT03945188: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo)
NCT03996369: Percentage of Participants Achieving Clinical Remission (Week 12): Etrasimod 2 mg 24.8% vs Placebo 15.2%; p==0.026 (Etrasimod 2 mg vs Placebo)
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT01863771: Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4)
NCT00488631: Number of Participants in Clinical Response Through Week 54 (Induction Baseline, Week 0 through Week 54): Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance 48/154 (31.2%) vs GLM-I-Rsp-Golimumab 50 mg Maintenance 71/151 (47.0%) vs GLM-I-Rsp-Golimumab 100 mg Maintenance 75/151 (49.7%); p=0.010 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 50 mg Maintenance), p=<0.001 (Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance vs GLM-I-Rsp-Golimumab 100 mg Maintenance)
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT05528510: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8)
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Hydrocortisone (Cortenema)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Hydrocortisone Acetate (Cortifoam)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Apriso)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Canasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Lialda)ApprovedSmall moleculeAminosalicylateReliable signal
NCT00151892: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months (6 Months): SPD476 83.7 percent of participants | Asacol 81.5 percent of participants
Mesalamine (Pentasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Mesalamine (Rowasa)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03524092: Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) (Week 40): Maintenance Period: Miri IR - 200 mg Miri SC 49.9% (95% CI 44.7 to 55) vs Maintenance Period: Miri IR - PBO SC 25.1% (95% CI 18.8 to 31.5)
NCT03518086: Percentage of Participants With Clinical Remission at Week 12 (Week 12): Placebo IV Q4W 13.3% (95% CI 6.9-19.6) vs 300 mg Mirikizumab IV Q4W 24.2% (95% CI 19.5-28.9); p=0.00006 (Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W)
Olsalazine (Dipentum)ApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Ozanimod (Zeposia)ApprovedSmall moleculeS1P receptorReliable signal
NCT02435992: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period))
NCT03915769: Clinical response at week 12: 52.9% (0.46 mg) and 61.5% (0.92 mg) vs 32.3% placebo.
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
INSPIRE/COMMAND: clinical remission + endoscopic improvement met
NCT03398148: Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score (Week 12): Substudy 1, Induction Period 1: Double-blind Placebo IV 1/60 (1.7%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV 7/61 (11.5%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV 6/61 (9.8%) vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV 6/58 (10.3%) vs Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV 42/340 (12.4%); p=0.0324 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV), p=0.0460 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV), p=0.0397 (Substudy 1, Induction Period 1: Double-blind Placebo IV vs Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV)
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3Reliable signal
NCT01458574: Percentage of Participants In Remission at Week 52 (Week 52): Tofacitinib 5 mg BID 34.3% vs Tofacitinib 10 mg BID 40.6% vs Placebo 11.1%; p=<0.0001 (Tofacitinib 5 mg BID vs Placebo), p=<0.0001 (Tofacitinib 10 mg BID vs Placebo)
NCT01458951: Percentage of Participants With Remission at Week 8 (Week 8): Tofacitinib 10 mg BID 16.6% vs Placebo BID 3.6%; p=0.0005 (Tofacitinib 10 mg BID vs Placebo BID)
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03653026: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (Week 8): Upadacitinib 45 mg 33.5% (95% CI 28.5-38.5) vs Placebo 4.1% (95% CI 1.1-7.1); p=<0.001 (Upadacitinib 45 mg vs Placebo)
NCT02819635: Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (At Week 8): SS1: Placebo 0% vs SS1: Upadacitinib 7.5 mg 8.5% vs SS1: Upadacitinib 15 mg 14.3% vs SS1: Upadacitinib 30 mg 13.5% vs SS1: Upadacitinib 45 mg 21.4%; p=0.049 (SS1: Placebo vs SS1: Upadacitinib 7.5 mg), p=0.010 (SS1: Placebo vs SS1: Upadacitinib 15 mg), p=0.007 (SS1: Placebo vs SS1: Upadacitinib 30 mg), p=<0.001 (SS1: Placebo vs SS1: Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT02407236: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Week 8): Induction Study (IS): Placebo Intravenous (IV) 17/319 (5.3%) vs IS: Ustekinumab 130 Milligram (mg) IV 50/320 (15.6%) vs IS: Ustekinumab Approximately 6 mg/kg IV 50/322 (15.5%); p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab 130 Milligram (mg) IV), p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab Approximately 6 mg/kg IV)
NCT04630028: Week 8 clinical remission 25% (27/107) after IV induction; the study's primary endpoint is week 52 remission in week 8 responders.
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinReliable signal
NCT02497469: Percentage of Participants Who Achieved Clinical Remission (Week 52): Adalimumab SC, 160/80/40 mg 22.5% (95% CI 18.5-27.0) vs Vedolizumab IV 300 mg 31.3% (95% CI 26.7-36.2); p=0.0061 (Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg)
NCT02611830: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 14.3% (95% CI 6.4-26.2) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 46.2% (95% CI 36.5-56.2) vs Maintenance Phase: Induction IV + Vedolizumab 300 mg IV 42.6% (95% CI 29.2-56.8); p=<0.001 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
Mesalamine (Asacol HD)US approval withdrawnSmall moleculeAminosalicylatePartial signalNo reviewed efficacy summary in this indication
AfimkibartPhase 3Monoclonal antibodyTL1APartial signal
NCT04090411: Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 (At Week 14): Induction Period: Placebo 11.6% (95% CI 5.77-22.88) vs Induction Period: PF-06480605 50 mg 25.5% (95% CI 15.44-37.19) vs Induction Period: PF-06480605 150 mg 23.3% (95% CI 14.98-33.98) vs Induction Period: PF-06480605 450 mg 23.9% (95% CI 16.58-32.06); p=0.0545 (Induction Period: Placebo vs Induction Period: PF-06480605 50 mg), p=0.0823 (Induction Period: Placebo vs Induction Period: PF-06480605 150 mg), p=0.0642 (Induction Period: Placebo vs Induction Period: PF-06480605 450 mg) missed
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
Icotrokinra (Icotyde)Phase 3PeptideIL-23 receptorReliable signal
NCT06049017: Primary endpoint clinical response at Week 12: 63.5% with the highest icotrokinra dose vs 27% with placebo (p<0.001)
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MufemilastPhase 3Small moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 3Small moleculemiR-124Reliable signal
NCT05535946: ABTECT maintenance, clinical remission at Week 44: placebo 10.4% (20), 25 mg 50.8% (98; placebo-adjusted +39.3%), 50 mg 51.3% (100; placebo-adjusted +40.3%), p<0.0001
NCT05507203: ABTECT-1 (NCT05507203), clinical remission at Week 8: placebo 2.5% (4/158), 25 mg 23.8% (38/160, p<0.0001), 50 mg 21.7% (69/318, p<0.0001; placebo-adjusted +19.3%)
PonesimodPhase 3Small moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1AReliable signal
NCT06052059: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints.
NCT04996797: Remission 26% vs 1% placebo; +25pp (95% CI 14–37)
AC-101Phase 2Small moleculeRIPK2not yet gradedNo reviewed efficacy summary in this indication
ALTB-268Phase 2Monoclonal antibodyPSGL-1Weak signalNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorReliable signal
NCT04857112: Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002)
ATH-063Phase 2Small moleculeG9A (EHMT2)Weak signalFeatured results are safety only in this race
BI 3032950Phase 2Monoclonal antibodyTREM-1not yet gradedNo reviewed efficacy summary in this indication
CU104Phase 2Small moleculeEndothelial barrier functionPartial signalNo reviewed efficacy summary in this indication
GarutadustatPhase 2Small moleculePHD1/2not yet gradedNo reviewed efficacy summary in this indication
HRS-7085Phase 2Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
HSK47388Phase 2PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
IPG11406Phase 2Small moleculeEBI2Weak signalFeatured results are safety only in this race
Live SK08Phase 2Microbiome therapeuticLive biotherapeutic productnot yet gradedNo reviewed efficacy summary in this indication
MK-8690Phase 2Monoclonal antibodyCD30 ligand (CD30L / CD153)not yet gradedNo reviewed efficacy summary in this indication
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Nanosomal TacrolimusPhase 2Small moleculeCalcineurinnot yet gradedNo reviewed efficacy summary in this indication
Nomelcitinib (D-2570)Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
OD-07656Phase 2Small moleculeRIPK2Weak signalNo reviewed efficacy summary in this indication
OlamkiceptPhase 2Protein / enzyme therapeuticIL-6 transPartial signal
NCT03235752: Clinical response at Week 12: 58.6% olamkicept 600mg vs 34.5% placebo, P=0.032.
OmilancorPhase 2Small moleculeLANCL2Partial signal
NCT03861143: Clinical Remission (Week 12): BT-11 Low-dose (440 mg) 30.3% | BT-11 High-dose (880 mg) 31.8% vs Placebo 22.7%
PALI-2108Phase 2Small moleculePDE4Weak signalFeatured results are safety only in this race
PicankibartPhase 2Monoclonal antibodyIL-23 p19Partial signal
NCT05377580: Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05).
PL8177Phase 2PeptideMC1Rnot yet gradedNo reviewed efficacy summary in this indication
ZotemtegrastPhase 2Small moleculeα4β7 integrinWeak signal
NCT05611671: Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) (Week 12): MORF-057 200 mg BID 31.9% | MORF-057 100 mg BID 23.9% | MORF-057 100 mg QD-M 17.1% vs Placebo 24.3% missed
NCT05291689: Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score (From baseline to 12 weeks): MORF-057 (Main Cohort) -6.4 score on a scale (Standard Deviation 11.18)
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 1/2Cell therapyAllogeneic MSC therapynot yet gradedNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ExoFloPhase 1Cell therapyMSC-derived exosomesWeak signalNo reviewed efficacy summary in this indication
LMT503Phase 1Small moleculeMacrophage polarization / Cellular metabolismnot yet gradedNo reviewed efficacy summary in this indication
R-3750Phase 1Biologic (subtype unspecified)Dendritic cell targetingnot yet gradedNo reviewed efficacy summary in this indication
SOR102Phase 1Biologic (subtype unspecified)TNF-alpha, IL-23 p19Weak signalFeatured results are safety only in this race
TQH3906Phase 1Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
BalinatunfibDiscontinuedSmall moleculeTNF-alphanot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 88 furthest-along competitors are listed; 26 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(34 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Remicade (infliximab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2026-11 · NCT05906576 · CT.gov ↗
What to watch
December 2026 (3)
Early phase / not applicableCrohn's DiseaseActive not recruiting
Est. primary completion 2026-12 · NCT06839820 · CT.gov ↗
What to watch
Phase 2Acute PancreatitisRecruiting
Est. primary completion 2026-12-15 · NCT03684278 · CT.gov ↗
What to watch
Early phase / not applicableCrohn's DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT06064864 · CT.gov ↗
What to watch
2027 (9)
January 2027 (1)
Phase 3SarcoidosisActive not recruiting
Est. primary completion 2027-01-12 · NCT05689879 · CT.gov ↗
What to watch
March 2027 (2)
Early phase / not applicableCrohn's DiseaseRecruiting
Est. primary completion 2027-03 · NCT06758024 · CT.gov ↗
What to watch
Phase 1/2Glaucoma Following SurgeryRecruiting
Est. primary completion 2027-03-01 · NCT05180994 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Metastatic MelanomaActive not recruiting
Est. primary completion 2027-06-30 · NCT05034536 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Relapsing PolychondritisRecruiting
Est. primary completion 2027-07 · NCT06941376 · CT.gov ↗
What to watch
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-07-30 · NCT05928039 · CT.gov ↗
What to watch
December 2027 (3)
Early phase / not applicableTakayasu ArteritisRecruiting
Est. primary completion 2027-12-15 · NCT07491913 · CT.gov ↗
What to watch
Phase 2Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT07657312 · CT.gov ↗
What to watch
Early phase / not applicableCheckpoint Inhibitor, Pilot Study, Diabetes MelletusNot yet recruiting
Est. primary completion 2027-12-31 · NCT07257068 · CT.gov ↗
What to watch
2028 (13)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
February 2028 (1)
Early phase / not applicableCrohn's DiseaseRecruiting
Est. primary completion 2028-02-13 · NCT07470502 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2Sjogren Syndrome, Sjogren Syndrome With Keratoconjunctivitis, Dry Eye Disease (DED)Not yet recruiting
Est. primary completion 2028-03 · NCT07671222 · CT.gov ↗
What to watch
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
Phase 4SchizophreniaRecruiting
Est. primary completion 2028-03 · NCT05823532 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3Ulcerative ColitisNot yet recruiting
Est. primary completion 2028-04-30 · NCT06614387 · CT.gov ↗
What to watch
June 2028 (1)
Phase 1/2Aneurysm, Stroke, Vasculitis, Tumor Necrosis Factor-alphaRecruiting
Est. primary completion 2028-06 · NCT02638701 · CT.gov ↗
What to watch
July 2028 (2)
Phase 4Oncology, Infusion ReactionRecruiting
Est. primary completion 2028-07 · NCT06031233 · CT.gov ↗
What to watch
Early phase / not applicableCardiac Arrest (CA), Post Cardiac Arrest SyndromeActive not recruiting
Est. primary completion 2028-07-31 · NCT07176754 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Depressive Disorder, Major, InflammationRecruiting
Est. primary completion 2028-08-31 · NCT06136546 · CT.gov ↗
What to watch
September 2028 (1)
Early phase / not applicableCrohn's DiseaseActive not recruiting
Est. primary completion 2028-09-01 · NCT07149441 · CT.gov ↗
What to watch
November 2028 (1)
Early phase / not applicableCrohn's DiseaseNot yet recruiting
Est. primary completion 2028-11-30 · NCT07424040 · CT.gov ↗
What to watch
December 2028 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2028-12-31 · NCT07510191 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
Phase 4Acute Kidney Injury, Acute Interstitial NephritisRecruiting
Est. primary completion 2029-01-15 · NCT07683975 · CT.gov ↗
What to watch
March 2029 (2)
Phase 4Crohn's DiseaseNot yet recruiting
Est. primary completion 2029-03-31 · NCT07415473 · CT.gov ↗
What to watch
Phase 4Crohn's DiseaseNot yet recruiting
Est. primary completion 2029-03-31 · NCT07417696 · CT.gov ↗
What to watch
October 2029 (1)
Early phase / not applicableCrohn's DiseaseRecruiting
Est. primary completion 2029-10-01 · NCT07314606 · CT.gov ↗
What to watch
2030 (4)
April 2030 (1)
Early phase / not applicableCrohn's DiseaseNot yet recruiting
Est. primary completion 2030-04-01 · NCT05584228 · CT.gov ↗
What to watch
June 2030 (3)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
Phase 4Ulcerative ColitisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07576452 · CT.gov ↗
What to watch
Phase 2Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity …Active not recruiting
Est. primary completion 2030-06-30 · NCT04305145 · CT.gov ↗
What to watch

See the full readout calendar ↗